Home Cart Sign in  
Chemical Structure| 13708-12-8 Chemical Structure| 13708-12-8

Structure of 13708-12-8

Chemical Structure| 13708-12-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 13708-12-8 ]

CAS No. :13708-12-8
Formula : C9H8N2
M.W : 144.17
SMILES Code : C1=CC=C2C(=C1C)N=CC=N2
MDL No. :MFCD00012335
InChI Key :CQLOYHZZZCWHSG-UHFFFAOYSA-N
Pubchem ID :61670

Safety of [ 13708-12-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 13708-12-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 10
Fraction Csp3 0.11
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 44.5
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

25.78 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.8
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.04
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.94
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.19
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.45
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.88

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.69
Solubility 0.293 mg/ml ; 0.00203 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.21
Solubility 0.89 mg/ml ; 0.00617 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.69
Solubility 0.0294 mg/ml ; 0.000204 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.73 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.28

Application In Synthesis of [ 13708-12-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 13708-12-8 ]

[ 13708-12-8 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 13708-12-8 ]
  • [ 817165-91-6 ]
  • 2
  • [ 13708-12-8 ]
  • [ 817165-91-6 ]
  • 5-methylquinoxaline N,N'-dioxide [ No CAS ]
  • 3
  • [ 517-21-5 ]
  • [ 2687-25-4 ]
  • [ 13708-12-8 ]
  • 5
  • [ 84312-25-4 ]
  • [ 933-67-5 ]
  • [ 13708-12-8 ]
  • [ 62-53-3 ]
  • [ 100-61-8 ]
  • 6
  • (2,6-Dimethyl-phenyl)-[2-(phenyl-hydrazono)-eth-(Z)-ylidene]-amine [ No CAS ]
  • [ 933-67-5 ]
  • [ 13708-12-8 ]
  • 7
  • [ 131543-46-9 ]
  • [ 2687-25-4 ]
  • [ 13708-12-8 ]
YieldReaction ConditionsOperation in experiment
98% With 10 wtpercent sulfated polyborate; In neat (no solvent); at 100℃; for 0.05h;Green chemistry; General procedure: To a mixture of substituted o-phenylenediamines derivative(2.0 mmol) and 1,2-diketone / alpha-hydroxy ketone (2.0 mmol),was added sulfated polyborate (10 wt%). The reaction mixture was stirred at 100 C in an oil bath. The reaction was monitored by thin layer chromatography (TLC). After completion of the reaction, the mixture was cooled to room temperature and quenched by water. The resultant product was filtered/extracted with EtOAc to get the product. Crude products were either recrystallized from ethanol or purified by column chromatography using silica as the stationary phase and EtOAc: pet. ether as mobile phase. The products obtained were known compounds and were identified by melting point and 1H and 13C NMR spectroscopy. The spectral data were compared with the literature values.
  • 8
  • [2-(Phenyl-hydrazono)-eth-(E)-ylidene]-o-tolyl-amine [ No CAS ]
  • [ 91-19-0 ]
  • [ 13708-12-8 ]
  • 9
  • [2-(Phenyl-hydrazono)-eth-(E)-ylidene]-m-tolyl-amine [ No CAS ]
  • [ 6344-72-5 ]
  • [ 13708-12-8 ]
  • 11
  • [ 13708-12-8 ]
  • [ 131454-80-3 ]
YieldReaction ConditionsOperation in experiment
63.6% With N-Bromosuccinimide; dibenzoyl peroxide; In 1,2-dichloro-ethane; at 110℃; for 4h; <strong>[13708-12-8]5-Methylquinoxaline</strong> (0.180 mL, 1.387 mmol, commercially available from, for example, Sigma-Aldrich), NBS (289 mg, 1.624 mmol), benzoyl peroxide (37 mg, 0.153 mmol) and 1,2- dichloroethane (4 mL) was stirred at 110 C for 2 h. Further portions of NBS (260 mg, 1.461 mmol)and benzoyl peroxide (31 mg, 0.128 mmol) were added and the reaction refluxed for a further 2 h. The solution was concentrated to give 1.1 g of a brown solid which was purified by chromatography on 5i02 (Biotage SNAP 50 g cartridge, eluting with O-100% diethylether/cyclohexane). The desired fractions were concentrated to give 5-(bromomethyl)quinoxaline (310 mg, 0.882 mmol, 63.6 % yield) as a yellow oil.LCMS (2 mm Formic): Rt=0.91 mi [MH] = 223, 225.
With bromine; dibenzoyl peroxide; at 70℃; for 10h; Example 4. Synthesis of TN-5In a 250 mL three-necked bottle was placed 5-methyl quinoxaline (2.88 g, 0.02 mol), benzoyl peroxide(20 mg) was added, CC14 (80 mL) was added, then the reaction was refluxed at 70 C for 10 hrs. The product was cooled and filtered to obtain a crude 2-bromomethyl quinoxaline, the compound was not separated, an excess amount of tert-butyl amine was added, and the reaction was stirred at room temperature for 3 hrs to obtain 5-methyl tert-butylamine quinoxaline (670 mg) in a yield of 15.6%.The above-obtained compound (670 mg, 0.003 mol) were added methanol (60 mL), Na2W04 '2H20 (O.lg) and 30%> H202 (3.5 mL), the reaction was proceeded at roomtemperature for 2.5 hrs. The product was separated by column chromatography (ethyl acetate : petroleum ether = 2: 1) to obtain a light yellow compound TN-4 (154 mg) in a yield of 21.5%.1HNMR (CDC13): 1.69 (s, 9H), 7.83 (dd, IH), 8.10 (dd, IH), 8.80 (d, IH), 8.87 (d, IH), 9.19 (s, IH), 9.96 (dd, IH); ESI-MS: 230 [M+H]+; Anal. (Ci3Hi5N30) C. H. N; found C 68.04%, H 6.95%, N 18.0%; requires: C, 68.10; H, 6.59; N, 18.33.
  • 12
  • [ 13708-12-8 ]
  • [ 3240-34-4 ]
  • acetic acid quinoxalin-5-ylmethyl ester [ No CAS ]
  • 13
  • [ 13708-12-8 ]
  • [ 64-19-7 ]
  • acetic acid quinoxalin-5-ylmethyl ester [ No CAS ]
  • acetic acid 1-oxy-quinoxalin-5-ylmethyl ester [ No CAS ]
  • [ 817165-91-6 ]
  • 14
  • [ 13708-12-8 ]
  • 5-methylquinoxaline N,N'-dioxide [ No CAS ]
  • 15
  • [ 13708-12-8 ]
  • tris(5-quinoxalinylmethyl)cyclotriguaiacylene [ No CAS ]
  • 18
  • [ 13708-12-8 ]
  • [ 93-59-4 ]
  • [ 77-48-5 ]
  • [ 131454-80-3 ]
YieldReaction ConditionsOperation in experiment
15.5 parts (100%) In tetrachloromethane; EXAMPLE 1 A mixture of 10 parts of <strong>[13708-12-8]5-methylquinoxaline</strong>, 10 parts of 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione, 1.7 parts of benzenecarboperoxoic acid and 318 parts of tetrachloromethane was stirred for 16 hours at reflux temperature under 2 lamps of 250 Watt. The reaction mixture was cooled and the organic layer was decanted. The product was filtered off and dried, yielding 15.5 parts (100%) of 5-(bromomethyl)quinoxaline (interm. 1).
  • 19
  • [ 13708-12-8 ]
  • 2-(3-cyanophenylamino)-N-[4-(1-trifluoroacetylpiperidin-4-yl)phenyl]acetamide [ No CAS ]
  • [ 34241-39-9 ]
  • 2-[N-(3-cyanophenyl)-N-(5-quinoxalinylmethyl)amino]-N-[4-(1-trifluoroacetylpiperidin-4-yl)phenyl]acetamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-Bromosuccinimide; sodium iodide; N-ethyl-N,N-diisopropylamine; In tetrachloromethane; isopropyl alcohol; Reference Example 74 2-[N-(3-Cyanophenyl)-N-(5-quinoxalinylmethyl)amino]-N-[4-(1-trifluoroacetylpiperidin-4-yl)phenyl]acetamide <strong>[13708-12-8]5-Methylquinoxaline</strong> (710 mg) and 920 mg of N-bromosuccinimide were dissolved in 8 ml of carbon tetrachloride, 50 mg of 2,2'-azobis(isobutyronitrile) was added to the solution, and the mixture was heated under reflux under an argon atmosphere for 5 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 8 ml of isopropanol. To the solution were added 0.60 ml of N-ethyldiisopropylamine, 418 mg of sodium iodide and 1.0 g of 2-(3-cyanophenylamino)-N-[4-(1-trifluoroacetylpiperidin-4-yl)phenyl]acetamide, and the mixture was heated under reflux for 45 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate-hexane) to give 560 mg of 2-[N-(3-cyanophenyl)-N-(5-quinoxalinylmethyl)amino]-N-[4-(1-trifluoroacetylpiperidin-4-yl)phenyl]acetamide. 1H-NMR(CDCl3) delta ppm: 1.56-1.72 (2H, m), 1.85-2.00 (2H, m), 2.70-2.93 (2H, m), 3.16-3.30 (1H, m), 4.05-4.17 (1H, m), 4.21 (2H, s), 4.60-4.72 (1H, m), 5.33 (2H, s), 7.00-7.19 (5H, m), 7.23-7.38 (3H, m), 7.53-7.61 (1H, m), 7.70-7.80 (1H, m), 8.05-8.26 (2H, m), 8.80-8.94 (2H, m)
  • 20
  • [ 13708-12-8 ]
  • palladium (II) acetate [ No CAS ]
  • [ 447456-97-5 ]
  • 21
  • [ 13708-12-8 ]
  • palladium (II) acetate [ No CAS ]
  • [ 447456-98-6 ]
  • 22
  • [ 13708-12-8 ]
  • bis(trimethylsilyl)acetylenetitanocene [ No CAS ]
  • [ 949163-61-5 ]
  • 23
  • [ 13708-12-8 ]
  • [ 18440-58-9 ]
  • [ 1204416-09-0 ]
  • 3,10-diacetyl-1,12-diphenyl-5-methyl-1,12,12a,12b-tetrahydrobis[1,2,4]triazolo[4,3-a:3',4'-c]quinoxaline [ No CAS ]
  • 24
  • [ 13708-12-8 ]
  • [ 58131-64-9 ]
  • [ 1204416-09-0 ]
  • [ 1204416-08-9 ]
  • 3,10-dimethoxycarbonyl-1,12-diphenyl-5-methyl-1,12,12a,12b-tetrahydrobis[1,2,4]triazolo[4,3-a:3',4'-c]quinoxaline [ No CAS ]
  • 25
  • [ 13708-12-8 ]
  • [ 121-92-6 ]
  • [ 1234503-53-7 ]
  • 26
  • [ 13708-12-8 ]
  • [ 447457-02-5 ]
  • 27
  • [ 13708-12-8 ]
  • [ 447457-04-7 ]
  • 28
  • [ 13708-12-8 ]
  • [ 447457-03-6 ]
  • 29
  • [ 13708-12-8 ]
  • [ 447457-01-4 ]
  • 30
  • [ 13708-12-8 ]
  • [ 447457-00-3 ]
  • 31
  • [ 13708-12-8 ]
  • [ 447457-07-0 ]
  • 32
  • [ 13708-12-8 ]
  • [ 447457-06-9 ]
  • 33
  • [ 13708-12-8 ]
  • [ 1354824-60-4 ]
  • 34
  • [ 13708-12-8 ]
  • [ 1354824-47-7 ]
  • 35
  • [ 617-86-7 ]
  • [ 13708-12-8 ]
  • C15H22N2Si [ No CAS ]
 

Historical Records

Categories

Related Parent Nucleus of
[ 13708-12-8 ]

Quinoxalines

Chemical Structure| 6344-72-5

A173049 [6344-72-5]

6-Methylquinoxaline

Similarity: 0.95

Chemical Structure| 6298-37-9

A161746 [6298-37-9]

Quinoxalin-6-amine

Similarity: 0.86

Chemical Structure| 17635-21-1

A231838 [17635-21-1]

2,3,6-Trimethylquinoxaline

Similarity: 0.83

Chemical Structure| 141234-08-4

A415664 [141234-08-4]

Quinoxaline-5-carbaldehyde

Similarity: 0.82

Chemical Structure| 53967-21-8

A480670 [53967-21-8]

6-(Bromomethyl)quinoxaline

Similarity: 0.82